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Sphingosine 1-phosphate (S1P) plays important roles in cardiovascular pathophysiology. S1P1 and/or
S1P3, rather than S1P2 receptors, seem to be predominantly expressed in vascular endothelial cells, while
S1P2 and/or S1P3, rather than S1P1 receptors, seem to be predominantly expressed in vascular smooth
muscle cells (VSMCs). S1P has multiple actions, such as proliferation, inhibition or stimulation of
migration, and vasoconstriction or release of vasoactive mediators. S1P induces an increase of the
intracellular Ca2þ concentration in many cell types, including VSMCs. Activation of S1P3 seems to play an
important role in Ca2þ mobilization. S1P induces cyclooxygenase-2 expression in VSMCs via both S1P2
and S1P3 receptors. S1P2 receptor activation in VSMCs inhibits inducible nitric oxide synthase (iNOS)
expression. At the local site of vascular injury, vasoactive mediators such as prostaglandins and NO
produced by VSMCs are considered primarily as a defensive and compensatory mechanism for the lack of
endothelial function to prevent further pathology. Therefore, selective S1P2 receptor antagonists may
have the potential to be therapeutic agents, in view of their antagonism of iNOS inhibition by S1P. Further
progress in studies of the precise mechanisms of S1P may provide useful knowledge for the development
of new S1P-related drugs for the treatment of cardiovascular diseases.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Sphingosine 1-phosphate (S1P) exposed on the vascular wall
plays important roles in cardiovascular pathophysiology. In the
vascular system, the major source of S1P is plasma, and S1P is
stored abundantly in hematopoietic cells such as red blood cells
and platelets, which lack the S1P-degrading enzyme S1P lyase
(1e4). Vascular endothelium has also emerged as a major
contributor of plasma S1P (5). S1P concentrations in human plasma
have been found in the range of 200e1000 nM (6e9). S1P in plasma
binds to albumin and lipoproteins, in particular to high-density
lipoproteins (HDLs). As S1P is the most active lipid component of
HDLs, it is responsible, at least in part, for many of the cardiovas-
cular effects of HDLs, including their ability to modulate vascular
tone, promote angiogenesis, inhibit/reverse atherosclerosis, and
protect against ischemia/reperfusion injury (10).achida).
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d/4.0/).Five S1P receptor subtypes (S1P1, S1P2, S1P3, S1P4, and S1P5)
have been identiﬁed in a wide variety of cells. These receptors are
coupled to multiple pertussis toxin (PTX)-sensitive and PTX-
insensitive G proteins (11). In several species, S1P1 and/or S1P3
receptors, rather than the S1P2 receptor, seem to be predominantly
expressed in vascular endothelial cells, while S1P2 and/or S1P3
receptors, rather than the S1P1 receptor, seem to be predominantly
expressed in vascular smooth muscle cells (VSMCs) (12e18). The
S1P1 receptor is coupled to Gi/o protein, while S1P2 and S1P3 re-
ceptors are coupled to Gq, Gi/o, G12/13 proteins. Through these
signaling cascades, S1P has multiple actions such as proliferation,
inhibition or stimulation of migration, and vasoconstriction or
release of vasoactive mediators (18e20). Modulation of vascular
tone by S1P was reviewed recently by Igarashi and Michel (21).
Under physiological condition, the function of VSMCs is regu-
lated by many factors such as vasoactive mediators, mechanical
forces, and neural transmitters. However, at a local site of vascular
injury, some of the vasoactive mediators produced by VSMCs are
considered primarily as a defensive and compensatory mechanism
for the lack of endothelial function to prevent further pathology. In
this context, a large amount of S1P is released from activatednese Pharmacological Society. This is an open access article under the CC BY-NC-ND
T. Machida et al. / Journal of Pharmacological Sciences 132 (2016) 211e217212platelets into the plasma, and this S1P is considered to affect the
functions of VSMCs directly and dramatically. In view of these
backgrounds, we will focus on the roles of S1P on the cellular
function and signaling pathways of VSMCs in this short review.
2. Intracellular calcium dynamics
Intracellular Ca2þ concentration ([Ca2þ]i) in VSMCs plays a
regulatory role as a second messenger in a variety of cellular
functions. S1P induces an increase of [Ca2þ]i in many cell types,
including VSMCs (22,23). Recent reports suggest that S1P3 activa-
tion plays an important role in Ca2þmobilization. We reported that
S1P induced a biphasic change in [Ca2þ]i, that is, a transient peak
increase followed by smaller sustained increases in [Ca2þ]i in
cultured rat aortic smooth muscle cells (SMCs) (24) (Fig. 1A). This
elevation was initiated at a concentration of more than 0.001 mM,
and a signiﬁcant increase in both peak and sustained [Ca2þ]i was
observed at more than 0.1 mM (Fig. 1B). We found that both
extracellular Ca2þ inﬂux and Ca2þ release from the sarcoplasmic
reticulum have a role in peak elevation. Transfection of small
interfering RNA (siRNA) targeting the S1P3 receptor signiﬁcantly
decreased both peak and sustained [Ca2þ]i (Fig. 1C). In addition,
Murakami et al. (25) reported that TY-52156, which is a selective[C
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Fig. 1. S1P increases [Ca2þ]i in VSMCs via the S1P3 receptor in cultured rat VSMCs. A: A re
dependent increase of [Ca2þ]i in VSMCs. The cells were stimulated with the indicated con
lation. C: Effect of S1P on [Ca2þ]i in VSMCs transfected with S1P receptor siRNA. The cells we
stimulation; at 5 min: [Ca2þ]i after stimulation. Symbols or bars show mean ± S.E.M. values
included in the symbol. *P < 0.01, **P < 0.001 vs. basal. yP < 0.001 vs. scrambled siRNA.
Adopted from Ref. (23) with permission.S1P3 receptor antagonist developed by their laboratory, prevented
the S1P-induced increase in [Ca2þ]i in human coronary arterial
SMCs. Tanaka et al. (23) have suggested that the Ca2þ response of
rat aortic myocytes to S1P progressively increases during culture
and that the mechanism by which this facilitatory response occurs
is associated with change of S1P3 receptor expression during cul-
ture. Activation of voltage-dependent Ca2þ channels, including L-
type Ca2þ channels, is considered to be mainly involved in this S1P-
induced increase of [Ca2þ]i. We also found that inhibition of
phospholipase C (PLC) and Gi protein completely and partially
inhibited the S1P-induced increase in [Ca2þ]i, respectively, in
VSMCs in both the presence and absence of extracellular Ca2þ. The
effects of these inhibitors were also found in rat HTC4 hepatoma
cells transfected with the S1P3 receptor (26). Taken together, S1P3
receptor-mediated PLC activation and intracellular Ca2þ mobiliza-
tion in VSMCs may only be mediated partially through Gi/o protein.
PLC is also activated by Gq protein, but it seems not to be activated
by G12/13 protein, because the Rho kinase inhibitor Y 27632 had no
effect.
It is reported that both extracellular and intracellular S1P can
activate store-operated Ca2þ entry (SOCE) in VSMCs (22, 24, 27, 28).
Hopson et al. (27) reported that S1P-induced Ca2þ entry was
inhibited by several SOCE inhibitors in primary aortic VSMCs andbasal 0.001 0.01 0.1 1 10
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presentative result. The cells were stimulated with S1P (1 mM). B: S1P concentration-
centrations of S1P. Peak: peak [Ca2þ]i after stimulation; at 5 min: [Ca2þ]i after stimu-
re stimulated with S1P. Basal: basal [Ca2þ]i before stimulation; peak: peak [Ca2þ]i after
of (n) experiments for B, n ¼ 10e11 experiments for C. When not visible, error bars are
T. Machida et al. / Journal of Pharmacological Sciences 132 (2016) 211e217 213furthermore reported that S1P activated stromal interaction
molecule 1 (STIM1). SOCE was observed in VSMCs that were
without either S1P2 or S1P3 receptors, and intracellular S1P acti-
vated SOCE by STIM1 recruitment to the plasma membrane,
strongly suggesting that not only extracellular but also intracellular
S1P can activate SOCE. Furthermore, they showed that the S1P-
induced SOCE contributes to constriction of cerebral arteries. The
role of intracellular S1P on SOCEwill be further discussed in Section
5, which addresses the role of sphingosine kinase in VSMCs. Tran-
sient receptor potential canonical (TRPC) proteins are now believed
to have an important role in not only SOCE but also receptor-
operated Ca2þ entry (ROCE). In fact, S1P reportedly activates
TRPC5 in human saphenous vein SMCs (22). TRPC5 is expressed in
the SMCs of human veins together with TRPC1, which forms a
complex with TRPC5, and S1P also activates TRPC5-TRPC1 hetero-
multimeric channels.
Furthermore, we have found that S1P can cause not only SOCE
but also ROCE in VSMCs (24), but the mechanisms of ROCE by S1P
are still largely unknown. Further studies are required to clarify the
detailed mechanisms.
There is increasing evidence that the immune modulator
FTY720, which is used as a treatment for multiple sclerosis, might
also be applied to cardiovascular diseases such as atherosclerosis.
FTY720 is phosphorylated by sphingosine kinase, and the phos-
phorylated compound is a potent agonist of S1P receptors, except
S1P2. In fact, FTY720 phosphate (FTY720-P) induces an increase in
[Ca2þ]i in Chinese hamster ovary (CHO) cells that stably express the
S1P3 receptor (25). Moreover, various selective S1P receptor ago-
nists have become commercially available. In addition to FTY720-P,
they could be useful tools to elucidate further the physiological
roles of S1P receptors in vascular cells.
3. Eicosanoid production
Eicosanoids produced by cyclooxygenase (COX) in the vascular
wall have important roles in cardiovascular pathophysiology. There
are two isoforms of COX: COX-1 and COX-2. COX-1 is constitutively
expressed in most cells, whereas COX-2 is induced in certain cell
types including VSMCs.
Recent studies have implicated a regulatory function of sphin-
golipids in prostanoid production (29). S1P reportedly induces
COX-2 expression and subsequently produces prostanoids in many
cells such as aortic SMCs (12, 18, 30), coronary artery SMCs (17),
tracheal SMCs (31), renal mesangial cells (32), and human amnion-
derived WISH cells (33). In aortic SMCs, we reported that S1P
(>1 mM) signiﬁcantly induced prostaglandin I2 (PGI2) production
(Fig. 2A), which is major arachidonic metabolite in rat aortic SMCs
(18). S1P-induced COX-2, but not COX-1, expression in VSMCs. Both
S1P2 and S1P3 receptors seem tomediate the induction of COX-2 by
S1P. Previously, we showed that suramin, an S1P3 receptor antag-
onist, signiﬁcantly inhibited S1P-induced COX-2 expression
(Fig. 2B). In addition, we conﬁrmed that the selective S1P2 receptor
antagonist JTE-013 (10 mM) also signiﬁcantly inhibited COX-2
expression (unpublished data). JTE-013 has been reported to
inhibit the speciﬁc binding of radiolabeled S1P to membranes of
CHO cells transfected with human and rat S1P2 receptors, with IC50
values of 17 ± 6 and 22 ± 9 nM, and has been reported to not affect
S1P binding to S1P3 and S1P1 at concentrations up to 10 mM
(34e36). In agreement with our results, both S1P2 and S1P3 re-
ceptors have been shown to be necessary for COX-2 induction in
human aortic SMCs (12). In coronary artery SMCs, Damirin et al.
(17) suggested that S1P-induced cAMP accumulation caused by
PGI2 synthesis is mediated mainly by the S1P2 receptor, although
they have not directly elucidated which S1P receptor subtype is
responsible for COX-2 induction. It has been reported that S1Pactivates nucleocytoplasmic shuttling of the mRNA-stabilizing
protein HuR, which in turn stabilizes COX-2 mRNA and elicits
COX-2 expression in macrophages (37). Thus, S1P presumably in-
creases COX-2 expression by inducing transcription of COX-2mRNA
and by stabilization of its mRNA in VSMCs.
Increased [Ca2þ]i by S1P has an important role in COX-2 in-
duction, since S1P has no effect on COX-2 expression under extra-
cellular and intracellular Ca2þ-depleted conditions and a protein
kinase C (PKC) inhibitor inhibits COX-2 induction (18). This Ca2þ-
dependent activation of PKC might be mediated by Gi and Gq, but
not G12/13, protein-coupled S1P receptors. Inhibition of Gi protein
by PTX partially inhibited COX-2 induction, while inhibition of Rho
kinase, which is the main signaling molecule of G12/13 protein,
failed to inhibit COX-2 induction.
Growing evidence suggests that HDL-associated S1P has a role
in the vascular protective effects of HDLs. In addition to their role in
reverse cholesterol transport, HDLs also exert beneﬁcial effects on
anti-oxidative, anti-inﬂammatory, anti-thrombotic, and
endothelium-dependent vasorelaxation (38,39). S1P is known as
the most active lipid component of HDLs and plays a key role in
vascular biology as an extracellular mediator (10). HDLs increase
PGI2 synthesis in both VSMCs and endothelial cells through a
mechanism involving COX-2 induction (12). Furthermore, both
HDL- and S1P-induced COX-2 inductions are diminished by either
S1P receptor antagonists (suramin, JTE-013, or VPC 23019) or
transfection of S1P2 and S1P3 siRNA (12). COX-2-derived prosta-
noids are now believed to be key protective molecules for the
cardiovascular system (40). Enhanced COX-2 induction in vascular
walls is considered to function primarily as a defensive and
compensatory mechanism for the lack of endothelial COX-1 func-
tion at the site of a local vascular injury associated with thrombosis,
atherosclerosis, and hypertension. In addition to its vasodilating
action, PGI2 has inhibitory effects on platelet aggregation and
adhesion, leukocyte adhesion, and VSMC proliferation/migration
(41). In fact, we reported that the production of PGI2 and inter-
leukin-1b (IL-1b)-induced COX-2 protein expression were lower in
VSMCs from spontaneously hypertensive rats-stroke prone
(SHRSP) than from normotensive Wistar Kyoto rats (42). It is
worthy to note that S1P-induced COX-2 expression in airway SMCs
is also considered to have a protective effect against asthma,
because of the enhancement of PGE2 production, which represses
b2-adrenergic activity by receptor desensitization (43).
As we discussed above, [Ca2þ]i elevation by S1P starts at a
concentration of more than 0.001 mM, and a signiﬁcant increase in
both peak and sustained [Ca2þ]i was observed at more than
0.1 mM, while PGI2 release by S1P starts at a concentration of more
than 0.1 mM. The nano-molar order of the S1P-induced increase in
[Ca2þ]i may have a physiological role in VSMCs, but the excessive
elevation of [Ca2þ]i by a micro-order of S1P may cause abnormal
vasoconstriction. The PGI2 released by S1P may have a role in the
amelioration of the abnormal situation via autocrine and/or para-
crine action.4. Nitric oxide production
Nitric oxide (NO) produced by NO synthase (NOS) in the
vascular wall plays important roles in cardiovascular pathophysi-
ology. In addition to its vasodilating action, NO has inhibitory ef-
fects on platelet aggregation and adhesion, leukocyte adhesion, and
VSMC proliferation/migration (44). There are three isoforms of
NOS: neuronal NOS, inducible NOS (iNOS), and endothelial NOS
(eNOS). eNOS is restricted to the endothelium, while iNOS is
expressed in several cell types including VSMCs following stimu-
lation with cytokines such as IL-1b.
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Fig. 2. S1P induces PGI2 production and COX-2 expression in cultured rat VSMCs. A: PGI2 production was determined by radioimmunoassay. The cells were treated with various
concentrations of S1P for 24 h. B: S1P induces COX-2 expression via S1P3 receptor. COX-2 protein expression was determined by western blotting. The cells were pretreated with or
without suramin (100 mM) for 1 h and then treated with or without S1P (1 mM) for 4 h. Upper: A representative image. Lower: Densitometric analysis expressed taking samples
treated with S1P alone as 100%. Bars show mean ± S.E.M. values of 4 and 6 experiments for A and B, respectively. **P < 0.01, vs. control. ##P < 0.01 vs. S1P alone.
Adopted from Ref. (18) with permission.
T. Machida et al. / Journal of Pharmacological Sciences 132 (2016) 211e217214We reported that S1P (>0.1 mM) inhibited IL-1b-induced NO
production and iNOS expression in VSMCs (19) (Fig. 3). This iNOS
inhibition was inhibited partially by PTX (19) (Fig. 3). Since this
effect of PTX disappeared under the Ca2þ-depleted condition,
S1P-induced iNOS inhibition was mediated partially by Ca2þ-
dependent Gi protein coupled to the S1P receptor. Conversely, the
Rho kinase inhibitor Y 27632 partially but signiﬁcantly attenu-
ated the inhibitory effect of S1P on iNOS expression in the Ca2þ-
depleted condition, but did not affect it in the presence of Ca2þ.
S1P also signiﬁcantly inhibited the IL-1b-induced persistent
activation of extracellular signal-regulated kinase (ERK), which is
necessary for IL-1b-induced iNOS expression, but had no effect in
the Ca2þ-depleted condition. This ERK inhibition was probably
mediated by Gq protein, because PTX did not affect this ERK
inhibition. Taken together, we conclude that S1P inhibits IL-1b-
induced iNOS expression in rat VSMCs through multiple mecha-
nisms involving both PTX-sensitive and -insensitive G proteins
coupled to S1P receptors. Furthermore, Ca2þ-dependent ERK
inhibition and Ca2þ-independent Rho kinase activation are
involved in the inhibitory mechanism of iNOS inhibition. We have
also observed that JTE-013 (10 mM) impaired the inhibitory effect
of S1P on iNOS protein expression, suggesting that the S1P2
receptor at least has a role in S1P-induced iNOS inhibition (un-
published data). In agreement with our results, S1P inhibits+
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Fig. 3. S1P inhibits IL-1b-induced NO production and iNOS expression in cultured rat VSMCs
stimulated with IL-1b for 24 h in the absence or presence of various concentrations of S1P. A
Eicom, Kyoto, Japan). Amount of NO expressed as a percentage, taking samples treated with
1b alone. B: A representative image of iNOS protein expression. The protein expression wa
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Adopted from Ref. (19) with permission.IL-1b-induced iNOS expression in rat mesangial cells and bovine/
human chondrocytes (45e47). Although signal transduction
seems to be different between these cells, this iNOS inhibition is
mediated by S1P2 receptor activation, since both JTE-013 and
knockdown of the S1P2 receptor by transfection with S1P2 siRNA
fully reversed IL-1b-induced iNOS expression in human chon-
drocytes (47).
Counteraction of IL-1b-induced iNOS expression by S1P in
chondrocytes from osteoarthritis patients may help to prevent
chronic inﬂammation. However, since iNOS induction in VSMCs is
also considered to function primarily as a defensive and compen-
satorymechanism for the lack of endothelial function at the site of a
local vascular injury associated with thrombosis, atherosclerosis,
and hypertension, S1P inhibition of NO production in VSMCs
may be of relevance to local pathophysiological conditions. In
fact, iNOS expression in VSMCs is negatively modulated by a
variety of vasoactive mediators such as angiotensin II (48) and
5-hydroxytryptamine (49,50), which cause vessel contraction and
VSMC proliferation. Furthermore, we reported that IL-1b-induced
NO production and iNOS expression in VSMCs derived from SHRSP
and under pressure stress, which simulates systolic hypertension,
were lower than in control cells (19,42). Therefore, selective S1P2
receptor antagonistsmay be helpful therapeutically, in viewof their
antagonism of iNOS inhibition by S1P.B
iNOS
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iNOS
β-actin
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+
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. The cells were untreated or pretreated with PTX (400 mg/ml) for 24 h. Cells were then
: NO production in the culture medium was measured by NOx Autoanalyzer (ENO-10,
IL-1b alone as 100%. Bars show mean ± S.E.M. values of 4 experiments. **P < 0.01 vs. IL-
s determined by western blotting. b-Actin protein expression was also evaluated as a
T. Machida et al. / Journal of Pharmacological Sciences 132 (2016) 211e217 2155. Role of sphingosine kinase in VSMCs
Recently, VSMCs have been shown to generate S1P intracellu-
larly by sphingosine kinase (SphK) from sphingosine. Two isoforms
of SphK have been identiﬁed: SphK1 and SphK2. Zhu et al. (51)
reported that corticotrophin-releasing factor (CRF) accelerates
S1P synthesis by inducing SphK1 expression in both A7r5 cells and
rat primary VSMCs. They showed that the synthesized S1P is
secreted and activates the S1P3 receptor. Since the SphK inhibitor
dimethylsphingosine (DMS) and the S1P3 receptor antagonist CAY
10444 inhibit CRF-induced VSMCs migration, they concluded that
S1P generation and S1P3 activation in VSMCs are responsible for
CRF-induced migration. Wilson et al. (28) have reported that
intracellular S1P generated by SphK1 has an important role in
angiotensin II (Ang II)-induced SOCE in VSMCs, showing that Ang II
activates SphK activity and increases intracellular S1P. They also
found that Ang II induces biphasic Ca2þ entry, consisting of an
immediate peak due to inositol tris-phosphate-dependent release
of intracellular Ca2þ, followed by a sustained transmembrane Ca2þ
inﬂux through SOCE, and that inhibition of SphK1 attenuates the
second phase of Ca2þ inﬂux. Furthermore, they found that genetic
deletion of SphK1 signiﬁcantly inhibits both the acute hypertensive
response to Ang II in anaesthetized SphK1 knockout mice and the
sustained hypertensive response to continuous infusion of Ang II in
conscious animals. This indicates that SphK1 in VSMCs plays a
critical role in the development of Ang II-induced hypertension. In
mouse BV2 microglial cells activated with lipopolysaccharide, DMS
inhibits iNOS mRNA expression, suggesting that SphK1 regulatesS1P2
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Fig. 4. Possible mechanisms of modulating VSMCs functions by S1P at a local site of vascula
The concentration-dependent changes of VSMCs function by S1P.NO signaling pathways (52). Although S1P negatively regulates
iNOS expression in VSMCs as mentioned above, it is possible that
the intracellular S1P generated by SphK1 affects iNOS expression
via autocrine/paracrine signaling mechanisms in VSMCs. In fact,
our preliminary experiments showed that DMS signiﬁcantly
potentiated IL-1b-induced iNOS expression and NO production in
VSMCs (unpublished data).
6. Clinical relevance
Under normal physiological conditions, vasoactive agents
derived from the endothelium and other tissues modulate endo-
thelial cell and VSMC function to maintain vascular homeostasis,
including vascular tone. Kerage et al. (53) have reported that
physiologically low concentrations of S1P (ca. 0.1 mM) are thought
to maintain the endothelial barrier, while pathophysiological con-
centrations of S1P (ca. 10 mM) disrupt the endothelial barrier and
increase vascular permeability. This indicates that S1P itself at high
concentrations, as well as other circulating vasoconstrictors, rea-
ches VSMCs through endothelial leakage. The high concentration of
S1P can cause an increase in [Ca2þ]i and induce PGI2 production in
VSMCs via the S1P3 receptor as we mentioned above.
S1P is known to play important roles in the pathogenesis of
atherosclerosis. Although the S1P3 receptor has been reported to
have some atheroprotective effects (12,54), the S1P2 receptor
instead plays a critical role in the development of atherosclerosis.
Twenty weeks of FTY720 treatment in apolipoprotein E deﬁcient
mice that were fed a high-cholesterol diet dramatically reducedS1P3
OX-2 expression
GI2 production
[Ca2+]i
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Ameliorate the abnormal 
VSMCs function ?
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r injury, such as atherosclerotic lesion. A: Role of S1P2 and S1P3 receptors in VSMCs. B:
T. Machida et al. / Journal of Pharmacological Sciences 132 (2016) 211e217216atherosclerotic lesion volume, macrophage, and collagen content
(55). Inhibition of the release of monocyte chemoattractant
protein-1 (MCP-1) via S1P3 receptor by VSMCs is thought to be
involved in the mechanisms. Wang et al. (56) have reported that
S1P2 receptor was expressed in macrophages, endothelial cells, and
SMCs in atherosclerotic aortas. In S1pr2/Apoe/mice fed a high-
cholesterol diet, the area of atherosclerotic plaques was markedly
decreased compared with S1pr2þ/þApoe/ mice. S1P2 receptor in
monocytes/macrophages promotes atherosclerosis through mech-
anisms including the regulation of modiﬁed LDL accumulation,
cytokine production, and cell migration. The activation of S1P2 re-
ceptors in endothelial cells inhibits eNOS activation and promotes
proinﬂammatory cytokines such as MCP-1. In VSMCs, the activation
of S1P2 receptor is assumed to destabilize plaques by decreasing the
density of a-smooth muscle actin-positive SMCs, which is likely
mediated through the inhibition of proliferation and SMC migra-
tion into the intima.
As we mentioned above, S1P is known as the most active lipid
component of HDL, an atheroprotective lipoprotein. Some athero-
protective effects of HDL such as eNOS activationwere shown to be
mediated via the S1P3 receptor (54). Thus, at local pathophysio-
logical sites with endothelial dysfunction, iNOS inhibition by S1P2
receptor activation in VSMCs may further magnify the atheroscle-
rosis. In this way, selective S1P2 receptor antagonists may be
helpful therapeutically for cardiovascular diseases, by antagonizing
of iNOS inhibition by S1P.
7. Conclusion
As shown in Fig. 4A, at a local site of vascular injury, some
vasoactive mediators such as prostaglandins and NO produced by
VSMCs are considered primarily as a defensive and compensatory
mechanism for the lack of endothelial function to prevent further
pathology. A large amount of S1P is released from activated plate-
lets into the plasma, and this S1P is considered to affect the func-
tions of VSMCs directly and dramatically. More than 1 mM S1P
signiﬁcantly induces an increase in [Ca2þ]i via S1P3 receptor acti-
vation, while it signiﬁcantly decreases IL-1b-induced NO produc-
tion via S1P2 receptor activation. COX-2 induction by S1P
stimulation is mediated by both S1P2 and S1P3 receptor activation
(Fig. 4A). As discussed above, the excessive elevation of [Ca2þ]i and
the inhibition of NO production by a micro-order of S1P may cause
abnormal vasoconstriction. The PGI2 released by S1P may have a
role in the amelioration of the abnormal situation via autocrine
and/or paracrine action (Fig. 4B). Furthermore, selective S1P2 re-
ceptor antagonists may be helpful therapeutically for cardiovas-
cular diseases, in view of their antagonism of iNOS inhibition by
S1P. Further progress in studies for the precise cellular and mo-
lecular mechanisms of S1P may provide useful knowledge for the
development of new S1P-related drugs for the treatment of car-
diovascular diseases.
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